Biogened Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Biogened.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth14.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding

May 23
Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding

Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

May 09
Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Feb 21
Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Is Biogened (WSE:BGD) A Risky Investment?

Feb 01
Is Biogened (WSE:BGD) A Risky Investment?

Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump

Feb 01
Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump

We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Jun 30
We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Oct 08
Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Is Biogened (WSE:BGD) A Risky Investment?

Jun 29
Is Biogened (WSE:BGD) A Risky Investment?

Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?

Mar 25
Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well

Dec 09
These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well

Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet

Jul 29
Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet

Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Apr 30
Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Is Biogened (WSE:BGD) A Risky Investment?

Jan 24
Is Biogened (WSE:BGD) A Risky Investment?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biogened has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

WSE:BGD - Analysts future estimates and past financials data (PLN Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20241004311N/A
12/31/2023965815N/A
9/30/2023924717N/A
6/30/2023904-29N/A
3/31/2023854-36N/A
12/31/2022803-36N/A
9/30/2022774-5-1N/A
6/30/202272402N/A
3/31/202270348N/A
12/31/202165223N/A
9/30/202157237N/A
6/30/202154247N/A
3/31/202150167N/A
12/31/202048179N/A
9/30/202049269N/A
6/30/202048158N/A
3/31/202048127N/A
12/31/201947126N/A
9/30/2019451-25N/A
6/30/2019441-24N/A
3/31/2019411-13N/A
12/31/2018401-14N/A
9/30/201839126N/A
6/30/201839104N/A
3/31/201836126N/A
12/31/2017341N/A6N/A
9/30/2017301N/A3N/A
6/30/2017311N/A4N/A
3/31/2017291N/A0N/A
12/31/2016291N/A-1N/A
9/30/2016322N/A-4N/A
6/30/2016312N/A-5N/A
3/31/2016313N/A-4N/A
12/31/2015303N/A0N/A
9/30/2015302N/A1N/A
6/30/2015261N/A2N/A
3/31/2015241N/A4N/A
12/31/2014231N/A1N/A
9/30/2014201N/A0N/A
6/30/2014211N/A-2N/A
3/31/2014221N/A-4N/A
12/31/2013222N/A-4N/A
9/30/2013242N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if BGD's forecast earnings growth is above the savings rate (3.7%).

Earnings vs Market: Insufficient data to determine if BGD's earnings are forecast to grow faster than the Polish market

High Growth Earnings: Insufficient data to determine if BGD's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if BGD's revenue is forecast to grow faster than the Polish market.

High Growth Revenue: Insufficient data to determine if BGD's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BGD's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.